http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 09:16:19 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Lunai+Bioworks+partners+with+BrainStorm+for+neurology+drug+discovery/26562423.html <p>Lunai Bioworks (NASDAQ: LNAI) and BrainStorm Therapeutics announced a collaboration to discover therapeutic targets for neurological diseases, according to a company statement. The partnership combines artificial intelligence-driven target discovery with human brain organoid modeling and zebrafish validation systems.</p><p>The collaboration received funding from the LouLou Foundation and will initially focus on rare genetic epilepsies and Parkinson's disease. BioSymetrics, Lunai's wholly owned subsidiary, will contribute AI-driven target discovery capabilities, while BrainStorm provides human-derived organoid systems.</p><p>The companies plan to integrate BrainStorm's Parkinson's disease midbrain organoid model with BioSymetrics' analysis of the Parkinson's Progression Markers Initiative dataset. This work aims to identify biomarkers and http://www.streetinsider.com/Corporate+News/Lunai+Bioworks+partners+with+BrainStorm+for+neurology+drug+discovery/26562423.html Thu, 28 May 2026 09:16:19 -0400 LNAI http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html <div class="xn-content"> <p><i>Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sacmto" idsrc="xmltag.org" >SACRAMENTO, Calif.</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>May 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks'</span> (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a newly awarded grant from the <span value="ACORN:5021602784" idsrc="xmltag.org" >LouLou Foundation</span>.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Lunai+Bioworks+and+BrainStorm+Therapeutics+Launch+Foundation-Funded+Parkinson%27s+and+Rare+Epilepsy+AI+Discovery+Collaboration/26562405.html Thu, 28 May 2026 09:15:00 -0400 A.27952506 A.35954321 A.50216027 LNAI O.17501370 O.20737027 O.25196667 O.56853832 http://www.streetinsider.com/Litigation/Federal+judge+grants+Lunai+expedited+discovery+in+naked+short+selling+case/26539212.html <p>A federal magistrate judge in Delaware granted Lunai Bioworks Inc. (NASDAQ: LNAI) permission to conduct expedited discovery to identify unnamed defendants accused of naked short selling the company's stock on the Nasdaq Stock Market.</p><p>The court order, issued May 20, allows Lunai to proceed with discovery before the typical timing under Federal Rules of Civil Procedure. The judge determined Lunai established "good cause" and demonstrated a prima facie case for its claims against the unidentified short sellers.</p><p>Lunai filed the lawsuit May 11 through law firms Dickinson Wright and Fox Rothschild, alleging securities fraud and market manipulation against "John Doe" defendants who http://www.streetinsider.com/Litigation/Federal+judge+grants+Lunai+expedited+discovery+in+naked+short+selling+case/26539212.html Fri, 22 May 2026 09:15:41 -0400 LNAI http://www.streetinsider.com/Short+Sales/Federal+judge+grants+Lunai+expedited+discovery+in+naked+short+selling+case/26539212.html <p>A federal magistrate judge in Delaware granted Lunai Bioworks Inc. (NASDAQ: LNAI) permission to conduct expedited discovery to identify unnamed defendants accused of naked short selling the company's stock on the Nasdaq Stock Market.</p><p>The court order, issued May 20, allows Lunai to proceed with discovery before the typical timing under Federal Rules of Civil Procedure. The judge determined Lunai established "good cause" and demonstrated a prima facie case for its claims against the unidentified short sellers.</p><p>Lunai filed the lawsuit May 11 through law firms Dickinson Wright and Fox Rothschild, alleging securities fraud and market manipulation against "John Doe" defendants who http://www.streetinsider.com/Short+Sales/Federal+judge+grants+Lunai+expedited+discovery+in+naked+short+selling+case/26539212.html Fri, 22 May 2026 09:15:41 -0400 LNAI http://www.streetinsider.com/Corporate+News/Federal+judge+grants+Lunai+expedited+discovery+in+naked+short+selling+case/26539212.html <p>A federal magistrate judge in Delaware granted Lunai Bioworks Inc. (NASDAQ: LNAI) permission to conduct expedited discovery to identify unnamed defendants accused of naked short selling the company's stock on the Nasdaq Stock Market.</p><p>The court order, issued May 20, allows Lunai to proceed with discovery before the typical timing under Federal Rules of Civil Procedure. The judge determined Lunai established "good cause" and demonstrated a prima facie case for its claims against the unidentified short sellers.</p><p>Lunai filed the lawsuit May 11 through law firms Dickinson Wright and Fox Rothschild, alleging securities fraud and market manipulation against "John Doe" defendants who http://www.streetinsider.com/Corporate+News/Federal+judge+grants+Lunai+expedited+discovery+in+naked+short+selling+case/26539212.html Fri, 22 May 2026 09:15:41 -0400 LNAI http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>May 22, 2026</chron></span> /PRNewswire/ -- On <chron>Wednesday, May 20, 2026</chron>, a <span>United States District Court</span> Magistrate Judge in <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> granted the Motion of <b><span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks, Inc.</span> </b>(Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "<person>John Doe</person>" "naked" short sellers of Lunai common stock on the <span>Nasdaq Stock Market</span> in late 2025 and throughout the first half of 2026. Co-lead counsel, <person>Jacob Frenkel</person>, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html Fri, 22 May 2026 09:15:00 -0400 A.07460948 A.09469586 A.25190968 LNAI O.00766871 O.02910753 O.03285413 O.17501370 http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>May 22, 2026</chron></span> /PRNewswire/ -- On <chron>Wednesday, May 20, 2026</chron>, a <span>United States District Court</span> Magistrate Judge in <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> granted the Motion of <b><span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks, Inc.</span> </b>(Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "<person>John Doe</person>" "naked" short sellers of Lunai common stock on the <span>Nasdaq Stock Market</span> in late 2025 and throughout the first half of 2026. Co-lead counsel, <person>Jacob Frenkel</person>, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html Fri, 22 May 2026 09:15:00 -0400 A.07460948 A.09469586 A.25190968 LNAI O.00766871 O.02910753 O.03285413 O.17501370 http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>May 22, 2026</chron></span> /PRNewswire/ -- On <chron>Wednesday, May 20, 2026</chron>, a <span>United States District Court</span> Magistrate Judge in <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> granted the Motion of <b><span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks, Inc.</span> </b>(Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "<person>John Doe</person>" "naked" short sellers of Lunai common stock on the <span>Nasdaq Stock Market</span> in late 2025 and throughout the first half of 2026. Co-lead counsel, <person>Jacob Frenkel</person>, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html Fri, 22 May 2026 09:15:00 -0400 A.07460948 A.09469586 A.25190968 LNAI O.00766871 O.02910753 O.03285413 O.17501370 http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>May 22, 2026</chron></span> /PRNewswire/ -- On <chron>Wednesday, May 20, 2026</chron>, a <span>United States District Court</span> Magistrate Judge in <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> granted the Motion of <b><span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks, Inc.</span> </b>(Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "<person>John Doe</person>" "naked" short sellers of Lunai common stock on the <span>Nasdaq Stock Market</span> in late 2025 and throughout the first half of 2026. Co-lead counsel, <person>Jacob Frenkel</person>, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html Fri, 22 May 2026 09:15:00 -0400 A.07460948 A.09469586 A.25190968 LNAI O.00766871 O.02910753 O.03285413 O.17501370 http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>May 22, 2026</chron></span> /PRNewswire/ -- On <chron>Wednesday, May 20, 2026</chron>, a <span>United States District Court</span> Magistrate Judge in <location value="LS/us.de" idsrc="xmltag.org" >Delaware</location> granted the Motion of <b><span value="NASDAQ-NMS:LNAI" idsrc="xmltag.org" >Lunai Bioworks, Inc.</span> </b>(Nasdaq: LNAI) (Lunai) to conduct expedited discovery to identify the "<person>John Doe</person>" "naked" short sellers of Lunai common stock on the <span>Nasdaq Stock Market</span> in late 2025 and throughout the first half of 2026. Co-lead counsel, <person>Jacob Frenkel</person>, Securities Enforcement Practice Chair at Dickinson Wright, stated: "This is the first step to amending the Complaint and holding accountable and pursuing substantial damages from http://www.streetinsider.com/Press+Releases/Federal+Judge+Orders+Expedited+Discovery+to+Identify+%27John+Doe%27+Defendants+%27Naked%27+Short-Sellers+of+Lunai+Common+Stock/26539205.html Fri, 22 May 2026 09:15:00 -0400 A.07460948 A.09469586 A.25190968 LNAI O.00766871 O.02910753 O.03285413 O.17501370